BRIM Biotechnology (TPE:6885) EBIT: NT$-450.41 Mil (TTM As of Dec. 2025)


TPE:6885 BRIM Biotechnology Inc TPE:6885
40 GF Score
Price NT$21.75
GF Value NT$486.91
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is BRIM Biotechnology EBIT?

BRIM Biotechnology TPE:6885 -0.46% 40 EBIT is NT$-450.41 Mil as of Dec. 2025. GuruFocus rates TPE:6885 with a GF Score™ of 40/100 and a GF Value™ of NT$486.91 (Possible Value Trap). The stock has 4 warning signs investors should review.

BRIM Biotechnology's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was NT$-171.86 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-450.41 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BRIM Biotechnology's annualized ROC % for the quarter that ended in Dec. 2025 was -119.25%. BRIM Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -3,227.10%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BRIM Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -24.36%.

BRIM Biotechnology  (TPE:6885) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BRIM Biotechnology's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-744.548 * ( 1 - 0% )/( (617.896 + 630.864)/ 2 )
=-744.548/624.38
=-119.25 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1934.358 - 34.563 - ( 1281.899 - max(0, 48.758 - 1334.795+1281.899))
=617.896

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1827.741 - 55.131 - ( 1158.429 - max(0, 66.941 - 1208.687+1158.429))
=630.864

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

BRIM Biotechnology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-687.452/( ( (16.862 + max(11.236, 0)) + (14.507 + max(-10.662, 0)) )/ 2 )
=-687.452/( ( 28.098 + 14.507 )/ 2 )
=-687.452/21.3025
=-3,227.10 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.205 + 0.799 + 46.742) - (34.563 + 0 + 1.947)
=11.236

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.632 + 0.67 + 46.165) - (55.131 + 0 + 2.998)
=-10.662

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BRIM Biotechnology's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-450.413/1849.327
=-24.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRIM Biotechnology EBIT Related Terms

BRIM Biotechnology EBIT Historical Data

* Premium members only.

The historical data trend for BRIM Biotechnology's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRIM Biotechnology EBIT Chart

BRIM Biotechnology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -105.34 -274.20 -687.87 -315.38 -450.41

BRIM Biotechnology Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -112.65 -69.83 -121.21 -87.51 -171.86

TPE:6885 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, BRIM Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRIM Biotechnology EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BRIM Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BRIM Biotechnology's EV-to-EBIT falls into.


TPE:6885
40GF Score
BRIM Biotechnology Inc TPE:6885
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRIM Biotechnology EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-450.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of NT$-450.41 Mil mean?
BRIM Biotechnology (TPE:6885) has a EBIT of NT$-450.41 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BRIM Biotechnology.
Is BRIM Biotechnology's EBIT too high?
BRIM Biotechnology's current EBIT is NT$-450.41 Mil. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's EBIT compare to VRTX and REGN?
BRIM Biotechnology's EBIT of NT$-450.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on BRIM Biotechnology. BRIM Biotechnology's current EBIT is NT$-450.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current EBIT is NT$-450.41 Mil. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current EBIT is NT$-450.41 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?

Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued. The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91. GuruFocus considers BRIM Biotechnology to be Possible Value Trap.

Key valuation signals for TPE:6885:

  • EBIT: NT$-450.41 Mil
  • GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BRIM Biotechnology Business Description

Address Alley 30, Lane 358, Ruiguang Road, 8th Floor, No.1, Neihu District, Taipei, TWN, 11492
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score

Get the complete analysis for TPE:6885

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$21.75
Price
NT$486.91
GF Value